Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Publication date: Sep 17, 2025

A key issue in the post-COVID-19 pandemic era is the ongoing administration of COVID-19 vaccines. Repeated vaccination is essential for preparing against currently circulating and newly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. However, optimizing vaccination strategies is crucial to efficiently manage medical resources and establish an effective vaccination framework. Therefore, a strategy to identify poor responders with lower sustained antibody titers would be beneficial because these individuals should be considered high priority for revaccination. We investigated longitudinal antibody titer data in a cohort of 2526 people in Fukushima, Japan, collected between April 2021 and November 2022. Using mathematical modeling and machine learning, we stratified the time-course patterns of antibody titers after two primary doses and one booster dose of COVID-19 messenger RNA vaccines. We identified three populations, which we refer to as the durable, the vulnerable, and the rapid-decliner populations, and approximately half of the participants remained in the same population after the booster dose. The rapid-decliner population experienced earlier infections than the others. Furthermore, when comparing spike protein-specific immunoglobulin G (IgG) titers, spike protein-specific IgA titers, and SARS-CoV-2-specific T cell responses between participants who experienced subsequent infections after booster vaccination and those who did not, we found that spike protein-specific IgA titers were lower during the early stage after booster vaccination in participants who went on to become infected with SARS-CoV-2. This approach could be used to inform policy decisions on vaccine distribution to maximize population-level immunity both in future pandemics and in the post-COVID-19 pandemic era.

Open Access PDF

Concepts Keywords
April Adult
Fukushima Aged
Mathematical Antibodies, Viral
Pandemic Antibodies, Viral
Vaccination COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Immunization, Secondary
Immunoglobulin G
Immunoglobulin G
Japan
Longitudinal Studies
Male
Middle Aged
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease IDO protein
disease IDO cell
disease MESH Park12
drug DRUGBANK Ademetionine
drug DRUGBANK Cysteamine
disease MESH breakthrough infection
disease MESH Infectious Diseases
disease IDO history
disease IDO blood
drug DRUGBANK Ethanol
disease MESH Hypertension
disease MESH Dyslipidemia
disease MESH Asthma
pathway KEGG Asthma
disease MESH Gout
disease MESH Rheumatism
disease MESH Anaphylaxis
drug DRUGBANK Acetaminophen
disease MESH Joint pain
drug DRUGBANK Esomeprazole
disease MESH heart disease
disease IDO production
drug DRUGBANK Proline
disease MESH viral load
disease IDO infectivity
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Aspartame
disease MESH lifestyle
disease IDO process
disease MESH seroconversion
disease MESH uncertainty
disease MESH viral infections
drug DRUGBANK Sulpiride
disease IDO immune response
disease MESH immunocompromised patients
disease MESH asymptomatic infections
drug DRUGBANK Hexocyclium
disease MESH sid
disease IDO assay
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Streptomycin
drug DRUGBANK Heparin
drug DRUGBANK Edetic Acid
disease IDO reagent
drug DRUGBANK Flunarizine
drug DRUGBANK Hyaluronic acid

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *